Assenagon Asset Management S.A. Decreases Stake in Hologic, Inc. (NASDAQ:HOLX)

Assenagon Asset Management S.A. cut its position in Hologic, Inc. (NASDAQ:HOLX) by 39.9% during the third quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The fund owned 383,885 shares of the medical equipment provider’s stock after selling 254,462 shares during the period. Assenagon Asset Management S.A. owned 0.16% of Hologic worth $31,271,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other large investors also recently modified their holdings of HOLX. Price T Rowe Associates Inc. MD boosted its holdings in shares of Hologic by 77.7% in the 1st quarter. Price T Rowe Associates Inc. MD now owns 6,297,197 shares of the medical equipment provider’s stock valued at $490,931,000 after buying an additional 2,753,016 shares in the last quarter. Swedbank AB purchased a new stake in Hologic in the first quarter valued at $120,827,000. Black Creek Investment Management Inc. boosted its stake in Hologic by 60.9% in the second quarter. Black Creek Investment Management Inc. now owns 2,338,970 shares of the medical equipment provider’s stock valued at $173,669,000 after acquiring an additional 885,524 shares in the last quarter. Mackenzie Financial Corp grew its holdings in shares of Hologic by 1,023.3% during the second quarter. Mackenzie Financial Corp now owns 895,699 shares of the medical equipment provider’s stock worth $66,506,000 after purchasing an additional 815,960 shares during the last quarter. Finally, Marshall Wace LLP acquired a new stake in shares of Hologic during the second quarter worth about $39,427,000. 94.73% of the stock is owned by hedge funds and other institutional investors.

Wall Street Analysts Forecast Growth

A number of analysts recently issued reports on the company. Leerink Partners decreased their target price on Hologic from $95.00 to $90.00 and set an “outperform” rating for the company in a research report on Tuesday, October 8th. Evercore ISI raised their target price on shares of Hologic from $78.00 to $82.00 and gave the stock an “in-line” rating in a research report on Tuesday, October 1st. Royal Bank of Canada reiterated a “sector perform” rating and issued a $82.00 price target on shares of Hologic in a research report on Friday, August 16th. Mizuho raised their price objective on shares of Hologic from $85.00 to $90.00 and gave the stock an “outperform” rating in a research report on Friday, October 4th. Finally, Stephens reaffirmed an “overweight” rating and issued a $92.00 target price on shares of Hologic in a report on Tuesday, July 30th. Five investment analysts have rated the stock with a hold rating and nine have issued a buy rating to the stock. According to MarketBeat, the company has a consensus rating of “Moderate Buy” and a consensus target price of $87.50.

Insider Activity

In related news, insider Benjamin Jordan Cohn sold 5,093 shares of the firm’s stock in a transaction on Thursday, August 1st. The stock was sold at an average price of $81.99, for a total transaction of $417,575.07. Following the transaction, the insider now directly owns 10,476 shares in the company, valued at $858,927.24. This trade represents a 0.00 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available through this hyperlink. In related news, insider Brandon Schnittker sold 476 shares of the stock in a transaction dated Tuesday, August 6th. The shares were sold at an average price of $83.11, for a total value of $39,560.36. Following the sale, the insider now owns 3,735 shares of the company’s stock, valued at $310,415.85. This trade represents a 0.00 % decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, insider Benjamin Jordan Cohn sold 5,093 shares of the firm’s stock in a transaction that occurred on Thursday, August 1st. The shares were sold at an average price of $81.99, for a total transaction of $417,575.07. Following the completion of the sale, the insider now owns 10,476 shares in the company, valued at $858,927.24. The trade was a 0.00 % decrease in their position. The disclosure for this sale can be found here. Company insiders own 1.75% of the company’s stock.

Hologic Stock Down 0.1 %

Shares of NASDAQ:HOLX opened at $80.83 on Friday. The firm has a market cap of $18.77 billion, a PE ratio of 27.49, a price-to-earnings-growth ratio of 2.96 and a beta of 0.98. The company has a fifty day simple moving average of $80.92 and a 200 day simple moving average of $77.86. The company has a current ratio of 3.99, a quick ratio of 3.32 and a debt-to-equity ratio of 0.51. Hologic, Inc. has a 12-month low of $64.02 and a 12-month high of $84.67.

Hologic (NASDAQ:HOLX) last released its earnings results on Monday, July 29th. The medical equipment provider reported $1.06 earnings per share for the quarter, topping the consensus estimate of $1.02 by $0.04. Hologic had a net margin of 17.59% and a return on equity of 19.53%. The company had revenue of $1.01 billion during the quarter, compared to the consensus estimate of $1 billion. During the same quarter in the previous year, the firm earned $0.93 EPS. The company’s revenue was up 2.7% on a year-over-year basis. On average, equities research analysts anticipate that Hologic, Inc. will post 4.09 EPS for the current fiscal year.

About Hologic

Hologic, Inc develops, manufactures, and supplies diagnostics products, medical imaging systems, and surgical products for women's health through early detection and treatment. The company operates through four segments: Diagnostics, Breast Health, GYN Surgical, and Skeletal Health. It provides Aptima molecular diagnostic assays to detect the infectious microorganisms; Aptima viral load assays for Hepatitis B virus, Hepatitis C virus, human immunodeficiency virus, and human cytomegalo virus; Aptima bacterial vaginosis and candida vaginitis assays for the diagnosis of vaginitis; Aptima SARS-CoV-2 and Panther Fusion SARS-CoV-2 assays to detect SARS-CoV-2; ThinPrep System for cytology applications; and Rapid Fetal Fibronectin Test that assists physicians in assessing the risk of pre-term birth.